NURS 5432 Midterm Study Guide Review, Study Guides, Projects, Research of Nursing

NURS 5432 Midterm Study Guide Review

Typology: Study Guides, Projects, Research

2025/2026

Available from 01/05/2026

bestlearner
bestlearner 🇰🇪

1.4K documents

1 / 26

Toggle sidebar

This page cannot be seen from the preview

Don't miss anything!

bg1
1 / 26
NURS 5432 Midterm Study Guide Review
1.
Abnormal growth and development: skin: Jaundice within the first 24 hours (pathologic,
possible hemolysis or
infection).
Petechiae,
purpura
(suggests
clotting
disorders
or
sepsis).
Birthmarks:
Café-au-lait
spots
(>6
or
>0.5
cm
in
size
may
indicate
neurofibromatosis).
Port-wine
stain
(may
indicate
Sturge-Weber syndrome).
2.
Abnormal
growth
and
development:
Head:
Bulging
fontanel
(increased
intracranial
pressure,
hydrocephalus).
Sunken
fontanel
(dehydration).
Craniosynostosis
(premature
suture
closure,
abnormal
head
shape).
Large
anterior
fontanel
(hypothyroidism,
Down
syndrome).
pf3
pf4
pf5
pf8
pf9
pfa
pfd
pfe
pff
pf12
pf13
pf14
pf15
pf16
pf17
pf18
pf19
pf1a

Partial preview of the text

Download NURS 5432 Midterm Study Guide Review and more Study Guides, Projects, Research Nursing in PDF only on Docsity!

1 / 26

NURS 5432 Midterm Study Guide Review

1. Abnormal growth and development: skin: Jaundice within the first 24 hours (pathologic, possible hemolysis or

infection). Petechiae, purpura (suggests clotting disorders or sepsis). Birthmarks: Café-au-lait spots (>6 or >0.5 cm in size may indicate neurofibromatosis). Port-wine stain (may indicate Sturge-Weber syndrome).

2. Abnormal growth and development: Head: Bulging fontanel (increased intracranial pressure,

hydrocephalus). Sunken fontanel (dehydration). Craniosynostosis (premature suture closure, abnormal head shape). Large anterior fontanel (hypothyroidism, Down syndrome).

2 / 26

3. Abnormal growth and development: Eyes: Absent red reflex (retinoblastoma, congential cataracts).

Hypertelorism (widely spaced eyes may indicate genetic syndromes like Down or Noonan syndrome). Purulent eye drainage is not normal usually indicative of infection gonorrhea,chlamydia, or herpes Persistent strabismus after 6 months.

4. Abnormal growth and development: Ears: Low-set ears (associated with renal or genetic

abnormality like Turner's or trisomy 21). Ear pits or tags (linked to renal anomalies).

5. Abnormal growth and development: Mouth: Cleft palate/lip (requires surgical evaluation).

Absent suck reflex (neurological impairment or prematurity). Macroglossia (associated with hypothyroidism, Beckwith-Wiedemann syndrome).

6. Abnormal growth and development: Neck: Webbing excessive amounts of skin Turner's or Noonan's syndrome

4 / 26 Cryptorchidism: Undescended testicles beyond 6 months. Hydrocele: Persistent beyond 1 year or associated with inguinal hernia.

11. Abnormal growth and development: Musculoskeletal: Developmental dysplasia of the hip (DDH):

Positive Ortolani/Barlow tests or asymmetric gluteal folds. Clavicular fracture: Crepitus, decreased arm movement on the attected side.

12. Childhood Immunization Schedule: Birth: Hep B

13. Childhood Immunization Schedule: 2 months: "2 Be DR HIP" B:

Hep B

5 / 26 D: DTaP (Diphtheria Tetanus acellular Pertussis) R: Rv (Rotovirus) H: HIB (Haemophilus Influenza Type B) I: IPV (Inactivated Polio Vaccine) P: PCV (Pneumococcal)

14. Childhood Immunization Schedule: 4 months: "4 DR HIP"

D: DTaP (Diphtheria Tetanus acellular Pertussis) R: Rv (Rotovirus) H: HIB (Haemophilus Influenza Type B) I: IPV (Inactivated Polio Vaccine) P: PCV (Pneumococcal)

15. Childhood Immunization Schedule: 6 months: "Be DR HIP IN 6 months"

B: Hep B

7 / 26 V: Varicella Zoster D: DTaP (Diphtheria Tetanus acellular Pertussis) I: IPV (Inactivated Polio Vaccine) M: MMR

18. Childhood Immunization Schedule: Age 11 - 12 years: "Tada!! Human Men"

T: TdaP H: Human papilloma Virus M: Meningococcal

19. Childhood Immunization Schedule: Age 16-18: "Men"

M: Meningococcal Booster (need for college)

20. CDC MMR recommendations: MMR Series of 2 (1 year and by 12 years) If

exposed can give as early as 6 months May be given simultaneously with TB testing with PPD, but prefer to postpone PPD for 4-6 weeks to avoid possible suppressive response to PPD

21. Vaccinations in pregnancy (okay to give): Flu, Tdap (EVERY pregnancy), RSV, and COVID- 19

8 / 26 vaccination

22. Vaccinations in pregnancy (contraindication): No live vaccines

Avoid Varicella,MMR, Zoster during pregnancy

23. Tanner stages: A widely used system that describes the 5 stages of pubertal development

24. Thelarche: onset of breast development

25. Tanner stage 1: girls: Age 8-

preadolescent, no breast, no pubic hair

26. Tanner stage 2: girls: Age 11-

Breast bud stage with elevation of breast and papilla; enlargement of areola. Pubic hair sparse, long, and straight.

27. Tanner stage 3: girls: Age 12-

Breast enlargement without separate nipple contour. Pubic hair fills out but is straight

28. Tanner stage 4 female: Age 14

10 / 26

32. Developmental Milestones by age: 6-9 months: Turns to sound Babbles

and combines vowel/consonant sounds Responds to name Rolls over Sits independently Transfers objects Supports weight on feet Uses thumb and fingers to pick up objects Crawls

33. Developmental Milestones by age: 10-12 months: Takes simple action on request Purposefully

says "mama" or "dada" Sits independently and plays Pulls to standing/cruise furniture Communicates by reaching and pointing Moves purposefully to get desired object Has increasing curiosity Recognizes people Uses both hands well

34. Developmental Milestones by age: 13-18 months: Scribbles with large crayon

11 / 26 Walks alone Feeds self with fingers and begins using a spoon 4-10 word vocabulary Follows simple directions Coordinates use of both hands Responds to name Points to 2 pictures upon request Long jabbering sentences Throw ball overhead

35. Developmental Milestones by age: 19-24 months: Walks up/down stairs Jumps with

both feet Completes simple puzzles, circle shapes first Stacks 6- blocks Uses 2-word sentences 30- word vocabulary

36. Complications of testicular torsion: testicular infarction, necrosis (loss of testis)

Treat within 6 hours. As time progresses chance of loss increases.

13 / 26 Prehn sign absent Absent creamastric reflex

38. benign prostatic hyperplasia (BPH): enlargement of the prostate gland, common in older men

50, causes urinary obstruction

39. benign prostatic hyperplasia (BPH) clinical manifestation: -Bladder distention, smooth/rubbery

nodules, enlarged prostate, urinary symptoms (frequency, nocturia, dribbling, retention), diflculty urinating -infection caused by retention

40. benign prostatic hyperplasia (BPH): Diagnostic: UA (r/o UTI), PSA (>4 abnormal),

uroflowmetry, normal BUN/Cr

41. benign prostatic hyperplasia (BPH): Treatment: Drug: alpha blockers ("-osin" : Alfuzosin, doxazosin,

Tamsulosin), 5-Alpha Reductase inhibitors (finasteride and dutasteride) for reducing prostate size. Surgical option: transurethral resection of the prostate (TURP)

42. Side effect of alpha-adrenergic antagonist agents: (Alfuzosin, doxazosin, Tamsulosin):

SE: orthostatic hypotension, dizziness

43. BP Management in Elderly Males: Ace inhibitors (-prils) ARBs

(-sartan)

14 / 26

44. BP Management in Elderly Males with BPH: • Alpha-blockers (Tamsulosin, Alfuzosin, Tera- zosin) ’Relax

bladder neck, lower BP.

  • Low-dose diuretics (HCTZ) ’Manage fluid retention.

45. Prostatitis: Acute or chronic inflammation of the prostate

(Usually Gram (-) like E. Coli)

46. Prostatitis Treatment: 1st line ABX: Fluoroquinolones (Cipro/Levo) x 4-6 weeks

*(Ciprofloxacin 500mg PO BID or Levofloxacin 500-750mg QD) 2nd line ABX: Sulfamethoxazole/trimethoprim 160 mg BID (check local resistance) **PLUS- NSAIDs and Alpha 1 Blockers for lower urinary tract symptoms ("-osin" : Alfuzosin, doxazosin, Tamsulosin)

47. Prostate Cancer: malignant neoplasm of the prostate gland; second most common cancer in men. High-fat diet increase risk.

48. Prostate Cancer: Clinical manifestation: S/S: Bladder distention, hard prostate w/ nodules.

*early: mimic BPH; late: bone pain, uremia

16 / 26

  • 50-59: <3.
  • 60-69: <4.
  • 70-79: <6.

58. Elevated PSA indication: More likelihood for dx of cancer

59. PAP Guidelines Age Specific Considerations: Pediatrics - screening under 21 not recommend- ed

Geriatrics - with adequate hx of screening and no CIN II in the last 20 years should not be screened Negative results 3 negative cytology 2 negative HPV + cytology (one in the last five years)

17 / 26

60. PAP Guidelines Pregnancy Considerations: Squamous lesions may progress during pregnan- cy but regress

after Colposcopy ONLY to exclusive invasive cancer in high-risk women Unless cancer is identified, treatment of CIN is contraindicated

61. CIN I (Bethesda Classification): mild dysplasia: neoplastic cells confined to lower 1/3 of epithelium

62. CIN III (Bethesda Classification): severe dysplasia (Carcinoma in situ): involvement up to the basement

membrane of epithelium

63. CIN II (Bethesda Classification): moderate dysplasia: involvement of 2/3 of epithelium

64. American Cancer Society (ACS) Pap Smear Guidelines: • Start at 25: Preferred HPV testing alone every 5

years OR

  • Co-testing (Pap + HPV) every 5 years
  • Cytology (Pap) alone every 3 years
  • Ages 30-65: Same options as above.

65. American College of Obstetricians and Gynecologists (ACOG) Pap Smears Guidelines: •

Start at 21: Cytology (Pap) alone every 3 years.

  • Ages 30-65: Choose one:
  • HPV testing alone every 5 years

19 / 26

  • Ages 40-44: Optional yearly mammograms.
  • Ages 45-54: Yearly mammograms recommended.
  • Ages 55+: Mammograms every 1-2 years, Screening continues with life expectancy of at least 10 more years. ***High risk add MRI to mammogram

70. hormone replacement therapy (HRT): replacement of hormones (estrogen and/or proges- terone) to treat

symptoms associated with menopause. Given to females with intact uterus

71. Medroxyprogesterone acetate (MPA) or natural progesterone given with estrogen:

hormone replacement therapy (HRT) Improves sleep disorders, urogenital atrophy, lowers risk of osteoporotic fractures, may improve mood

72. hormone replacement therapy (HRT) contraindications: *estrogen-dependent malig- nancies

*unexplained uterine bleeding *history of thromboembolism or stroke *coronary artery disease *active liver disease

20 / 26

73. ERT (estrogen replacement therapy): Given to females without a uterus (otherwise increases the risk of endometrial

cancer without opposing progesterone)

74. Conjugated Estrogens (Premarin): estrogen hormone; comes from pregnant mare urine

75. Estradiol: synthetic, comes in lower dosages

Formulations: Estrace (vaginal cream), Estring (vaginal ring), Vagifem (vaginal tablet), Vivelle-Dot, Alora, Climara (patch)

76. Differentials for vaginal bleeding: Ectopic pregnancy

Pregnancy termination Placental abruption